Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04867616 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 466
- Enrollment target
NCT04867616 is a Phase 2 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 466 participants.
The verdict
NCT04867616, a Phase 2 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 466 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease (AD).
Interventions
- OTHER Placebo
- BIOLOGICAL Bepranemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04867616
The ClinicalTrials.gov registry entry for NCT04867616 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04867616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04867616 about?
NCT04867616 is a clinical study titled "A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)". The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease (AD).
What is the current status of trial NCT04867616?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 466 participants. The study started on 2021-06-09. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT04867616?
The interventions under investigation include: Placebo (OTHER), Bepranemab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04867616?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.